There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Exelixis (EXEL), Aileron Therapeutics (ALRN) and Silence Therapeutics (SLN) with bullish sentiments.
Exelixis (EXEL)
In a report issued on October 26, Andy Hsieh from William Blair reiterated a Buy rating on Exelixis. The company’s shares closed last Friday at $19.96.
According to TipRanks.com, Hsieh is a 5-star analyst with an average return of 19.9% and a 61.1% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Seattle Genetics, and Beyondspring.
Exelixis has an analyst consensus of Moderate Buy, with a price target consensus of $31.29, implying a 50.5% upside from current levels. In a report issued on October 19, Needham also assigned a Buy rating to the stock with a $33.00 price target.
See today’s analyst top recommended stocks >>
Aileron Therapeutics (ALRN)
William Blair analyst Matt Phipps maintained a Buy rating on Aileron Therapeutics on October 26. The company’s shares closed last Friday at $1.18.
According to TipRanks.com, Phipps has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.9% and a 35.9% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Pieris Pharmaceuticals, and Atara Biotherapeutics.
Currently, the analyst consensus on Aileron Therapeutics is a Strong Buy with an average price target of $4.00, implying a 217.5% upside from current levels. In a report issued on October 26, JonesTrading also reiterated a Buy rating on the stock with a $5.00 price target.
Silence Therapeutics (SLN)
Silence Therapeutics received a Buy rating from William Blair analyst Myles Minter on October 27. The company’s shares closed last Wednesday at $14.48.
According to TipRanks.com, Minter is a 4-star analyst with an average return of 11.0% and a 30.3% success rate. Minter covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Minerva Neurosciences, and Prevail Therapeutics.
Silence Therapeutics has an analyst consensus of Moderate Buy.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
